Phase I Clinical Study on the Long-term Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Solid tumor.
Phase 1
- Conditions
- Refractory Solid Tumor
- Registration Number
- JPRN-UMIN000008006
- Lead Sponsor
- Mie University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse effects.
- Secondary Outcome Measures
Name Time Method Immune response, QOL, and the change in serum PSA (prostate cancer only).